It has been confirmed that disruption of SIRT7 expression or administration of a selective HDAC8 inhibitor enhances antitumor immunity and efficacy of ICB in HCC (Xiang et al., 2020; Yang et al., 2021). Here, SIRT7 is linked to hepatocellular carcinoma.